Global RNAi Drugs Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global RNAi Drugs Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
It refers to the highly conservative, double stranded RNA induced, highly specific degradation of homologous mRNA in the evolutionary process
RNAi Drugs report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global RNAi Drugs market is projected to reach US$ 268930 million in 2029, increasing from US$ 69200 million in 2022, with the CAGR of 21.4% during the period of 2024 to 2029. Demand from Hospital and Clinic are the major drivers for the industry.
Increasing incidence of chronic medical and genetic disorders such as cancer and cardiovascular diseases (CVDs) across the globe is one of the key factors driving the market growth. Moreover, rising geriatric population, who are more susceptible to these diseases, is also driving the growth of the market. In line with this, as the coronavirus disease (COVID-19) continues to spread globally, the demand for RNAi drug delivery technology has also increased significantly. Targeted drug delivery approaches, such as aptamer delivery systems, are gaining enormous traction for the delivery of antiviral drugs because they are induced by small interfering RNA (siRNA) and can inhibit the expression of viral antigens. Furthermore, various technological advancements such as the development of innovative synthetic delivery vehicles and biological carriers are expected to drive the market growth. Nanocarriers, including siRNA or microRNA (miRNA), are crucial for the development of personalized medicine and the identification of altered cellular molecules and metabolites. Other factors, including extensive research and development (R&D) activities in nanotechnology and molecular diagnostics, and overall improvement in healthcare infrastructure are expected to further drive the market.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global RNAi Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Alnylam
Novo Nordisk
Eli Lilly
Alexion
Novartis
Roche
Arrowhead Pharmaceuticals Inc.
CureVac AG
Dicerna Pharmaceuticals Inc.
Gradalis Inc.
Ionis Pharmaceuticals Inc
Merck & Co. Inc.
Moderna Inc.
SBI ALApharma
Silence Therapeutics Plc
Sirnaomics Inc.
Segment by Type
siRNA
shRNA
Other
Hospital
Clinic
Other
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the RNAi Drugs market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of RNAi Drugs, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the RNAi Drugs industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of RNAi Drugs in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, RNAi Drugs introduction, etc. RNAi Drugs Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of RNAi Drugs market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
RNAi Drugs report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global RNAi Drugs market is projected to reach US$ 268930 million in 2029, increasing from US$ 69200 million in 2022, with the CAGR of 21.4% during the period of 2024 to 2029. Demand from Hospital and Clinic are the major drivers for the industry.
Increasing incidence of chronic medical and genetic disorders such as cancer and cardiovascular diseases (CVDs) across the globe is one of the key factors driving the market growth. Moreover, rising geriatric population, who are more susceptible to these diseases, is also driving the growth of the market. In line with this, as the coronavirus disease (COVID-19) continues to spread globally, the demand for RNAi drug delivery technology has also increased significantly. Targeted drug delivery approaches, such as aptamer delivery systems, are gaining enormous traction for the delivery of antiviral drugs because they are induced by small interfering RNA (siRNA) and can inhibit the expression of viral antigens. Furthermore, various technological advancements such as the development of innovative synthetic delivery vehicles and biological carriers are expected to drive the market growth. Nanocarriers, including siRNA or microRNA (miRNA), are crucial for the development of personalized medicine and the identification of altered cellular molecules and metabolites. Other factors, including extensive research and development (R&D) activities in nanotechnology and molecular diagnostics, and overall improvement in healthcare infrastructure are expected to further drive the market.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global RNAi Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Alnylam
Novo Nordisk
Eli Lilly
Alexion
Novartis
Roche
Arrowhead Pharmaceuticals Inc.
CureVac AG
Dicerna Pharmaceuticals Inc.
Gradalis Inc.
Ionis Pharmaceuticals Inc
Merck & Co. Inc.
Moderna Inc.
SBI ALApharma
Silence Therapeutics Plc
Sirnaomics Inc.
Segment by Type
siRNA
shRNA
Other
Segment by Application
Hospital
Clinic
Other
Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the RNAi Drugs market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of RNAi Drugs, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the RNAi Drugs industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of RNAi Drugs in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, RNAi Drugs introduction, etc. RNAi Drugs Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of RNAi Drugs market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices